Richard Mountfield
General Counsel bei CONSTELLATION PHARMACEUTICALS, INC.
Profil
Richard Mountfield is currently the Senior Vice President-Regulatory Affairs & Quality at Constellation Pharmaceuticals, Inc. and the SVP-Regulatory Affairs & Quality at Aura Biosciences, Inc. Previously, he held positions as the VP-Global Regulatory Affairs at Celyad Oncology SA and the Senior VP-Regulatory Affairs & Drug Development at Boston Pharmaceuticals, Inc. Dr. Mountfield obtained a doctorate degree from the University of Aberystwyth.
Aktive Positionen von Richard Mountfield
Unternehmen | Position | Beginn |
---|---|---|
CONSTELLATION PHARMACEUTICALS, INC. | General Counsel | - |
AURA BIOSCIENCES, INC. | General Counsel | - |
Ehemalige bekannte Positionen von Richard Mountfield
Unternehmen | Position | Ende |
---|---|---|
Boston Pharmaceuticals, Inc.
Boston Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Boston Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that leverages a drug development team to advance a portfolio of high value candidates that address important unmet medical needs. The company was founded by Robert Armstrong and Chris Viehbacher and is headquartered in Cambridge, MA. | General Counsel | - |
CELYAD ONCOLOGY SA | General Counsel | - |
Ausbildung von Richard Mountfield
University of Aberystwyth | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
AURA BIOSCIENCES, INC. | Health Technology |
CELYAD ONCOLOGY SA | Health Technology |
Private Unternehmen | 2 |
---|---|
Constellation Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Boston Pharmaceuticals, Inc.
Boston Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Boston Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that leverages a drug development team to advance a portfolio of high value candidates that address important unmet medical needs. The company was founded by Robert Armstrong and Chris Viehbacher and is headquartered in Cambridge, MA. | Commercial Services |